Switch theme
Sign up to access all valuation multiples
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one fourth of Stryker's total revenue currently comes from outside the United States.
1946
53K+
LTM Revenue $23.5B
LTM EBITDA $6.6B
$161B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Stryker has a last 12-month revenue (LTM) of $23.5B and a last 12-month EBITDA of $6.6B.
In the most recent fiscal year, Stryker achieved revenue of $22.6B and an EBITDA of $5.7B.
Stryker expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Stryker valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $23.5B | XXX | $22.6B | XXX | XXX | XXX |
| Gross Profit | $15.2B | XXX | $14.4B | XXX | XXX | XXX |
| Gross Margin | 65% | XXX | 64% | XXX | XXX | XXX |
| EBITDA | $6.6B | XXX | $5.7B | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 25% | XXX | XXX | XXX |
| EBIT | $6.0B | XXX | $4.7B | XXX | XXX | XXX |
| EBIT Margin | 26% | XXX | 21% | XXX | XXX | XXX |
| Net Profit | $4.9B | XXX | $3.0B | XXX | XXX | XXX |
| Net Margin | 21% | XXX | 13% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $9.9B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Stryker's stock price is $383.
Stryker has current market cap of $146B, and EV of $161B.
See Stryker trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $161B | $146B | XXX | XXX | XXX | XXX | $12.67 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Stryker has market cap of $146B and EV of $161B.
Stryker's trades at 7.1x EV/Revenue multiple, and 28.1x EV/EBITDA.
Equity research analysts estimate Stryker's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Stryker has a P/E ratio of 29.9x.
See valuation multiples for Stryker and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $146B | XXX | $146B | XXX | XXX | XXX |
| EV (current) | $161B | XXX | $161B | XXX | XXX | XXX |
| EV/Revenue | 6.8x | XXX | 7.1x | XXX | XXX | XXX |
| EV/EBITDA | 24.4x | XXX | 28.1x | XXX | XXX | XXX |
| EV/EBIT | 26.6x | XXX | 34.4x | XXX | XXX | XXX |
| EV/Gross Profit | 10.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 29.9x | XXX | 48.9x | XXX | XXX | XXX |
| EV/FCF | 48.2x | XXX | 46.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialStryker's last 12 month revenue growth is 9%
Stryker's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Stryker's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Stryker's rule of X is 51% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Stryker and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 20% | XXX | XXX | XXX |
| Rule of 40 | 33% | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 51% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 43% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Stryker acquired XXX companies to date.
Last acquisition by Stryker was XXXXXXXX, XXXXX XXXXX XXXXXX . Stryker acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Stryker founded? | Stryker was founded in 1946. |
| Where is Stryker headquartered? | Stryker is headquartered in United States of America. |
| How many employees does Stryker have? | As of today, Stryker has 53K+ employees. |
| Who is the CEO of Stryker? | Stryker's CEO is Mr. Kevin A. Lobo. |
| Is Stryker publicy listed? | Yes, Stryker is a public company listed on NYS. |
| What is the stock symbol of Stryker? | Stryker trades under SYK ticker. |
| When did Stryker go public? | Stryker went public in 1988. |
| Who are competitors of Stryker? | Similar companies to Stryker include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Stryker? | Stryker's current market cap is $146B |
| What is the current revenue of Stryker? | Stryker's last 12 months revenue is $23.5B. |
| What is the current revenue growth of Stryker? | Stryker revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Stryker? | Current revenue multiple of Stryker is 6.8x. |
| Is Stryker profitable? | Yes, Stryker is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Stryker? | Stryker's last 12 months EBITDA is $6.6B. |
| What is Stryker's EBITDA margin? | Stryker's last 12 months EBITDA margin is 28%. |
| What is the current EV/EBITDA multiple of Stryker? | Current EBITDA multiple of Stryker is 24.4x. |
| What is the current FCF of Stryker? | Stryker's last 12 months FCF is $3.3B. |
| What is Stryker's FCF margin? | Stryker's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of Stryker? | Current FCF multiple of Stryker is 48.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
